Clinical Trial Update: Sunitinib Malate and Capecitabine in Treating Patients With Unresectable or Metastatic Liver Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of sunitinib malate and capecitabine in adults with unresectable or metastatic hepatocellular carcinoma; the study was …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Sutent (sunitinib malate) (sunitinib malate)
• Xeloda (capecitabine) (capecitabine)

Snippet

Sponsor: University of Washington | Conditions: Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer | Phase 2 | Status: TERMINATED | Results posted: 2017-06-01